Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1998 2
1999 1
2003 1
2005 1
2008 3
2010 1
2012 1
2022 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR; Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Stryjewski ME, et al. Clin Infect Dis. 2008 Jun 1;46(11):1683-93. doi: 10.1086/587896. Clin Infect Dis. 2008. PMID: 18444791 Clinical Trial.
Characteristics of 34 adults with psychogenic excoriation.
Arnold LM, McElroy SL, Mutasim DF, Dwight MM, Lamerson CL, Morris EM. Arnold LM, et al. Among authors: lamerson cl. J Clin Psychiatry. 1998 Oct;59(10):509-14. doi: 10.4088/jcp.v59n1003. J Clin Psychiatry. 1998. PMID: 9818631
Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents.
Kimball AB, Gold MH, Zib B, Davis MW; Clobetasol Propionate Emulsion Formulation Foam Phase III Clinical Study Group. Kimball AB, et al. J Am Acad Dermatol. 2008 Sep;59(3):448-54, 454.e1. doi: 10.1016/j.jaad.2008.04.020. Epub 2008 Jun 9. J Am Acad Dermatol. 2008. PMID: 18539358 Clinical Trial.
Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.
Schachner LA, Lamerson C, Sheehan MP, Boguniewicz M, Mosser J, Raimer S, Shull T, Jaracz E; US Tacrolimus Ointment Study Group. Schachner LA, et al. Among authors: lamerson c. Pediatrics. 2005 Sep;116(3):e334-42. doi: 10.1542/peds.2004-2638. Pediatrics. 2005. PMID: 16140675 Clinical Trial.
14 results